Aktienanalyse zu Cryoport Inc (CYRX)CYRXCryoport Inc

Cryoport, Inc. is a provider of integrated, temperature-controlled supply chain solutions for the life sciences. The Company operates through two segments: segments: Life Sciences Services and Life Sciences Products. Its life sciences services include BioLogistics and BioStorage/BioServices, which provides temperature-controlled logistics, biostorage and bioservices within the life science industry through direct sales. Its life sciences products segment manufactures and sells cryogenic systems, such as freezers and cryogenic dewars and related ancillary accessories used in the storage and transport of life science commodities through direct sales or a distribution network. Its operating units include Cryoport Systems, CryoGene and MVE Biological Solutions (MVE). Cryoport Systems provides temperature-controlled BioLogistics, BioServices, and cryopreservation solutions, supporting clinical and commercial workflows through transport, kit production, labeling, packaging, and others. It operates in the Industrials sector (PHARMACEUTICAL PREPARATIONS industry).

Cryoport Inc (CYRX) is a good buy right now due to its current price of $16.84, which is below several analyst price targets, including $19 from Guggenheim and $21 from Roth Capital. The company's recent revenue growth of 16% year-over-year in Q1 2026, reaching $47.8 million, demonstrates strong market demand and operational performance. However, the main risk is its negative net income margin of -16.86% as of Q2 2026, which indicates ongoing losses that investors should monitor closely.

4 analysts cover CYRX: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 11.00.